bioRxivMicrobiology
Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy
M. Mistretta, M. Cimino, P. Campagne, S. Volant, E. Kornobis, O. Hebert, C. Rochais, P. Dallemagne, C. Lecoutey, C. Tisnerat, A. Lepailleur, Y. Ayotte, S. R. LaPlante, N. Gangneux, M. Zahorszka, J. Kordulakova, S. Vichier-Guerre, F. Bonhomme, L. Pokorny, M. Albert, J.-Y. Tinevez, G. Manina
Abstract
Drug-recalcitrant infections are a leading global-health concern. Bacterial cells benefit from phenotypic variation, which can suggest effective anti-microbial strategies. However, probing phenotypic variation entails spatiotemporal analysis of individual cells that is technically challenging, and hard to integrate into drug discovery. To address this, we developed a flow-controlled multi-condition microfluidic platform suitable for imaging two-dimensional growth of bacterial cells, compressed inside separate microchambers by a soft hydro-pneumatic membrane. With this platform, we implemented a dynamic single-cell screening for compounds that induce a phenotypic change while decreasing cell-to-cell variation, aiming to undermine the bacterial population, making it more vulnerable to other drugs. We first applied this strategy to mycobacteria, as tuberculosis poses a major public-health threat. Our top hit impairs Mycobacterium tuberculosis via a peculiar mode of action and enhances other anti-tubercular drugs. This work proves that pheno-tuning compounds represent a successful approach to tackle pathogens that are increasingly difficult to treat.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Dynamics of drug response in single mycobacterial cells by microfluidic dose-response assay
M. Mistretta, N. Gangneux, G. Manina·bioRxiv·Apr 3, 2022
- A high-throughput whole cell screen to identify inhibitors of Mycobacterium tuberculosis
J. Ollinger, A. Kumar, … T. Parish·bioRxiv·Sep 27, 2018
- Construction of lux-based promoter-reporter platforms in Mycobacterium bovis BCG for screening of drug repurposing small-molecule compounds as new anti-tuberculosis drugs
L. Zhu, A. W.-t. Lee, … G. K. H. Siu·bioRxiv·Nov 5, 2021
- The Dictyostelium discoideum - Mycobacterium marinum infection model, a powerful high throughput screening platform for anti-infective compounds
Jahn Nitschke, Nabil Hanna, Thierry Soldati·Frontiers in MicrobiologyPeer-reviewed·Jul 4, 2025
- Identification of novel chemical scaffolds that inhibit the growth of Mycobacterium tuberculosis in macrophages
S. Ahmed, A. J. Manning, … T. Parish·bioRxiv·Sep 28, 2021
- Rapid Screening and Validation of Intracellularly Active Antimycobacterial Compounds with Efficacy in Cellular and Murine Tuberculosis Models
Mahima Madan, Kanika Bisht, … Vivek Rao·bioRxiv·Sep 23, 2025